AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2024
Jun 20, 2024
30849_dirs_2024-06-20_54d62418-b577-49a3-8976-3f4848a487c4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2024-06-18
Reporting Person: Arbuckle Stuart A (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-18 | Stock Option (right to buy) | $41.39 | A | 14000 | Acquired | 2034-06-17 | Common Stock (14000) | Direct |
| 2024-06-18 | Restricted Stock Units | $ | A | 4000 | Acquired | Common Stock (4000) | Direct |
Footnotes
F1: The options fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date.
F2: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F3: The restricted stock units fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.